Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Avalo Therapeutics Inc

AVTX ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: STRONG BUY

Last Close

$19.59

▲ +0.72%

Market Cap $1.05B · Vol 171.94K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$1.05B

Small Cap

Div Yield

N/A

EPS Growth

+54.10%

YoY

RSI (14)

50.80

Momentum

Beta

0.76

vs Market

52W High

$24.27

19.28% below

52W Low

$8.51

130.20% above

Volume

171.94K

Avg 303.30K

P/B

4.05

Price-to-book

ROE

N/A

Return on equity

Free Float

97.16%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Avalo Therapeutics Inc (AVTX) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does AVTX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+6.93%

+6.35%

+3.05%

+37.38%

YTD

+7.87%

+118.88%

-41.70%

-99.76%

Financials & Valuation

TTM · Annual

Total Revenue	$59.00K
Net Income	$-78,259,000.00
Revenue Growth (YoY)	N/A
Gross Margin	100.00%
Operating Margin	-123,601.69%
Net Profit Margin	-132,642.37%
ROE	N/A
ROA · ROIC	-58.46% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	4,125.96
P/B	4.05
P/FCF	N/A
EPS Growth	+54.10%
Outstanding Shares	53.63M

Technical Indicators

50-Day SMA	$17.68
200-Day SMA	$16.67
RSI (14)	50.80
Beta	0.76
52-Week High	$24.27
52-Week Low	$8.51

Volume Today	171.94K
Avg Daily Volume (30D)	303.30K
Relative Volume	0.57x
Volatility (10D)	42.40
Volatility (30D)	57.65
Free Float	97.16%

Analyst Consensus

STRONG BUY

Current Price $19.59

Mean Target $44.92

52W Low$8.51 52W High$24.27

Current

Target

$8.51 $24.27

Current Analyst target

+129.28% upside potential · 14 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001V1GPQ9

ISINUS05338F3064

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 4, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The Company's lead asset is AVTX-009, an anti-IL-1? mAb, targeting inflammatory diseases. AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1? (IL-1?) with high affinity and neutralizes its activity. IL-1? is a central driver in the inflammatory process. Overproduction or dysregulation of IL-1? is implicated in many autoimmune and inflammatory diseases. IL-1? is a major, validated target for therapeutic intervention. There is evidence that inhibition of IL-1? could be effective in hidradenitis suppurativa and a variety of inflammatory diseases in dermatology, gastroenterology, and rheumatology. AVTX-009 is in the Phase II LOTUS trial for hidradenitis suppurativa (HS).